Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM4B | O94953 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | JMJD6 | Q6NYC1 | 11/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26966622 | 0.81 | KDM4A (0.44) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL19480884 | 0.81 | KEAP1 (0.44) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL30509529 | 0.76 | KMT2A (0.46) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL22230356 | 0.72 | KEAP1 (0.50) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL16035670 | 0.71 | KEAP1 (0.46) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL18448976 | 0.70 | KDM4A (0.44) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL16561285 | 0.70 | KMT2A (0.39) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL38658394 | 0.70 | S1PR2 (0.38) | KDM4AKDM4BKDM5BJMJD6KMT2A | |
| SCHEMBL38657463 | 0.70 | KDM4A (0.39) | KDM4AKDM4BKDM5BKMT2AKEAP1 | |
| SCHEMBL18157906 | 0.68 | KMT2A (0.64) | KDM4AKDM4BKDM5BJMJD6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | KDM4A 2564/4885KDM4B 2481/4885KDM5B 2435/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | KDM4A 2995/4885KDM4B 3000/4885KDM5B 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.